Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease
- PMID: 31031161
- DOI: 10.1016/j.jcf.2019.04.011
Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease
Abstract
Background: Clinical data indicate that airway inflammation in children with cystic fibrosis (CF) arises early, is associated with structural lung damage, and predicts progression. In bronchoalveolar lavage fluid (BALF) from CFTR mutant mice, several aspects of lipid metabolism are abnormal that contributes to lung disease. We aimed to determine whether lipid pathway dysregulation is also observed in BALF from children with CF, to identify biomarkers of early lung disease and potential therapeutic targets.
Methods: A comprehensive panel of lipids that included Sphingolipids, oxylipins, isoprostanes and lysolipids, all bioactive lipid species known to be involved in inflammation and tissue remodeling, were measured in BALF from children with CF (1-6 years, N = 33) and age-matched non-CF patients with unexplained inflammatory disease (N = 16) by HPLC-MS/MS. Lipid data were correlated with chest CT scores and BALF inflammation biomarkers.
Results: The ratio of long chain to very long chain ceramide species (LCC/VLCC) and lysolipid levels were enhanced in CF compared to non-CF patients, despite comparable neutrophil counts and bacterial load. In CF patients both LCC/VLCC and lysolipid levels correlated with inflammation and chest CT scores. The ceramide precursors Sphingosine, Sphinganine, Sphingomyelin, correlated with inflammation, whilst the oxidative stress marker isoprostane correlated with inflammation and chest CT scores. No correlation between lipids and current bacterial infection in CF (N = 5) was observed.
Conclusions: Several lipid biomarkers of early CF lung disease were identified, which point toward potential disease monitoring and therapeutic approaches that can be used to complement CFTR modulators.
Keywords: Bronchoalveolar lavage; Isoprostanes; Lysolipids; Mass spectrometry (5); Oxylipins.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis.J Cyst Fibros. 2020 Nov;19(6):902-909. doi: 10.1016/j.jcf.2020.01.010. Epub 2020 Feb 10. J Cyst Fibros. 2020. PMID: 32057679 Free PMC article.
-
Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis.J Cyst Fibros. 2019 Nov;18(6):790-795. doi: 10.1016/j.jcf.2019.04.012. Epub 2019 Apr 25. J Cyst Fibros. 2019. PMID: 31029606
-
Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients.PLoS One. 2015 Apr 28;10(4):e0125326. doi: 10.1371/journal.pone.0125326. eCollection 2015. PLoS One. 2015. PMID: 25919295 Free PMC article.
-
Noninvasive biomarkers of airway inflammation in cystic fibrosis.Curr Opin Pulm Med. 2003 Nov;9(6):516-21. doi: 10.1097/00063198-200311000-00012. Curr Opin Pulm Med. 2003. PMID: 14534405 Review.
-
Unravelling the role of sphingolipids in cystic fibrosis lung disease.Chem Phys Lipids. 2016 Oct;200:94-103. doi: 10.1016/j.chemphyslip.2016.08.002. Epub 2016 Aug 31. Chem Phys Lipids. 2016. PMID: 27592248 Review.
Cited by
-
A universal stress protein upregulated by hypoxia has a role in Burkholderia cenocepacia intramacrophage survival: Implications for chronic infection in cystic fibrosis.Microbiologyopen. 2023 Feb;12(1):e1311. doi: 10.1002/mbo3.1311. Microbiologyopen. 2023. PMID: 36825886 Free PMC article.
-
Metabolomics of airways disease in cystic fibrosis.Curr Opin Pharmacol. 2022 Aug;65:102238. doi: 10.1016/j.coph.2022.102238. Epub 2022 May 29. Curr Opin Pharmacol. 2022. PMID: 35649321 Free PMC article. Review.
-
Pseudomonas aeruginosa Consumption of Airway Metabolites Promotes Lung Infection.Pathogens. 2021 Jul 29;10(8):957. doi: 10.3390/pathogens10080957. Pathogens. 2021. PMID: 34451421 Free PMC article. Review.
-
Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.Front Immunol. 2023 Feb 16;14:1107437. doi: 10.3389/fimmu.2023.1107437. eCollection 2023. Front Immunol. 2023. PMID: 36875141 Free PMC article.
-
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.Int J Mol Sci. 2020 Jun 15;21(12):4257. doi: 10.3390/ijms21124257. Int J Mol Sci. 2020. PMID: 32549377 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical